uses JavaScript to provide the best possible experience for our content, but your browser has it disabled. Learn how to enable it here.


Posted January 12, 2021

Seller of Cholesterol, Weight Loss Products, and More Warned for Claims

On November 17, 2020, the FDA issued a warning letter to Bonagens following a review of the company's website, which found statements made about the company's products Anti-Aging Supports, Cholesterol & Diabetes Control, Gout Control, Hypertension Control, Liver Supports, Lungs Supports, Vita-V for Men, and Weight Lost to be drug claims.

For example, Cholesterol & Diabetes Control was promoted with statements such as "Administration of Cholesterol/Diabetes Control has a significant decrease in fasting blood glucose and suppression of glucose elevation. It also stimulates the insulin secreting cell lines and helps to control blood glucose."

See ConsumerLab's Cholesterol-Lowering Supplements Review (Sterols/Stanols and Policosanol) for tests of related products.

Weight Lost was promoted with statements such as "In local tissues, liver, and adipose tissue, Weight Lost administration significantly reduced... abnormal phenotypical changes in both tissues."

See ConsumerLab's Weight Loss Supplements Review (7-Keto DHEA, Forskolin and Stimulant Blend Supplements) for tests of related products.

In addition, the products were found to be misbranded because they do not contain adequate directions for safe use, as required by federal regulations.

For more information, use the link below.

Warning Letter: Bonagens

See related warnings:

FDA Warns Seller of Evening Primrose Oil and Beta Glucan

FDA Warns Seller of Curcumin and Cholesterol Supplements

FDA Warns Immusist for Drug Claims

FDA Warns Seller of Digestive Enzymes, Nattokinase, and More

Seller of Cholesterol-Lowering Supplements Warned for Drug Claims